Summit

MDA-supported biotechnology company Summit PLC and the University of Oxford will collaborate on development of utrophin modulators to treat Duchenne/Becker MD

posted on November 25, 2013 - 9:28am
MDA-supported biotechnology company Summit PLC has entered into a collaboration with the University of Oxford (United Kingdom) for continued development of utrophin modulators to treat Duchenne muscular dystrophy (DMD) and possibly Becker muscular dystrophy (BMD).

Summit PLC, an MDA-supported biotechnology company in the UK, has received approval to test its experimental DMD drug SMT C1100 in boys with this disorder

posted on November 12, 2013 - 5:00am
  Update (Feb. 2, 2014): Results of this trial are expected during the second quarter of 2014. For more information about this United Kingdom-based trial, see Phase 1b Study of SMT C1100 in Subjects with Duchenne Muscular Dystrophy; or enter NCT02056808 into the search box at ClinicalTrials.gov.